The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy
Open accessAbstract
IgA nephropathy (IgAN) is an important cause of ESKD for which there are no approved therapies. A challenge for evaluating treatments for IgAN is the usual long time course for progression to ESKD. The aim of this Kidney Health Initiative project was to identify surrogate end points that could serve as reliable predictors of a treatment's effect on long-term kidney outcomes in IgAN and be used as a basis for approval. Proteinuria was identified as the most widely recognized and well studied risk factor for progression to ESKD in IgAN. The workgroup performed a critical review of the data on proteinuria reduction as a surrogate end point for a treatment's effect on progression to ESKD in IgAN. Epidemiologic data indicate a strong and consistent relationship between the level and duration of proteinuria and loss of kidney function. Trial-level analyses of data from 13 controlled trials also show an association between treatment effects on percent reduction of proteinuria and treatment effects on a composite of time to doubling of serum creatinine, ESKD, or death. We conclude that data support the use of proteinuria reduction as a reasonably likely surrogate end point for a treatment's effect on progression to ESKD in IgAN. In the United States, reasonably likely surrogate end points can be used as a basis for accelerated approval of therapies intended to treat serious or life-threatening conditions, such as IgAN. The clinical benefit of products approved under this program would need to be verified in a postmarketing confirmatory trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Surrogate End Points in Clinical Trials: Are We Being Misled?
Fleming, T. R., & DeMets, D. L. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-7-199610010-00011 · Cited by 1,651
A Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran, D. C., Coppo, R., Cook, H. T., Feehally, J., Roberts, I. S. D., Troyanov, S., Alpers, C. E., Amore, A., Barratt, J., et al. (2009) · Kidney International · doi:10.1038/ki.2009.243 · Cited by 1,235
Self-citationTrimarchi, H., Barratt, J., Cattran, D. C., Cook, H. T., Coppo, R., Haas, M., Liu, Z.-H., Roberts, I. S. D., Yuzawa, Y., Zhang, H., et al. (2017) · Kidney International · doi:10.1016/j.kint.2017.02.003 · Cited by 1,192
Self-citationA Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Roberts, I. S. D., Cook, H. T., Troyanov, S., Alpers, C. E., Amore, A., Barratt, J., Berthoux, F., Bonsib, S., Bruijn, J. A., et al. (2009) · Kidney International · doi:10.1038/ki.2009.168 · Cited by 1,038
Self-citationIntensive supportive care plus immunosuppression in IgA nephropathy
Rauen, T., Eitner, F., Fitzner, C., Sommerer, C., Zeier, M., Otte, B., Panzer, U., Peters, H., Benck, U., Mertens, P. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1415463 · Cited by 726
Self-citationRemission of Proteinuria Improves Prognosis in IgA Nephropathy
Reich, H. N., Troyanov, S. A. A., Scholey, J. W., & Cattran, D. C. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007050526 · Cited by 639
Self-citationLv, J., Zhang, H., Wong, M. G., Jardine, M. J., Hladunewich, M., Jha, V., Monaghan, H., Zhao, M., Barbour, S., Reich, H., et al. (2017) · JAMA · doi:10.1001/jama.2017.9362 · Cited by 540
Self-citationNatural history of idiopathic IgA nephropathy and factors predictive of disease outcome
D’Amico, G. (2004) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2004.01.001 · Cited by 500
Coppo, R., on behalf of the VALIGA study of the ERA-EDTA Immunonephrology Working Group, Troyanov, S., Bellur, S., Cattran, D., Cook, H. T., Feehally, J., Roberts, I. S. D., Morando, L., Camilla, R., et al. (2014) · Kidney International · doi:10.1038/ki.2014.63 · Cited by 498
Self-citationPredicting renal outcome in IgA nephropathy.
Radford, M. G., Donadio, J. V., Bergstralh, E. J., & Grande, J. P. (1997) · Journal of the American Society of Nephrology · doi:10.1681/asn.v82199 · Cited by 440
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Self-citationLevey, A. S., Gansevoort, R. T., Coresh, J., Inker, L. A., Heerspink, H. L., Grams, M. E., Greene, T., Tighiouart, H., Matsushita, K., Ballew, S. H., et al. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2019.06.009 · Cited by 591
Self-citationLong-Term Outcomes in IgA Nephropathy
Pitcher, D., Braddon, F., Hendry, B., Mercer, A., Osmaston, K., Saleem, M. A., Steenkamp, R., Wong, K., Turner, A. N., Wang, K., et al. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000135 · Cited by 458
Self-citationThe pathogenesis of IgA nephropathy and implications for treatment
Cheung, C. K., Alexander, S., Reich, H. N., Selvaskandan, H., Zhang, H., & Barratt, J. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00885-3 · Cited by 222
Self-citationRovin, B. H., Barratt, J., Cook, H. T., Noronha, I. L., Reich, H. N., Suzuki, Y., Tang, S. C. W., Trimarch, H., & Floege, J. (2025) · Kidney International · doi:10.1016/j.kint.2025.04.004 · Cited by 206
Self-citation
Metadata
- Authors
- Thompson, A., Carroll, K., A. Inker, L., Floege, J., Perkovic, V., Boyer-Suavet, S., W. Major, R., I. Schimpf, J., Barratt, J., Cattran, D. C., S. Gillespie, B., Kausz, A., W. Mercer, A., Reich, H. N., H. Rovin, B., West, M., & Nachman, P. H.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2019-01-11
- Volume
- 14
- Issue
- 3
- Pages
- 469-481
- ISSN
- 1555-9041 (ISSN-L)
- 1555-905X
- OpenAlex
- W2911011964
- Cited by
- 317
- References
- 44
- FWCI
- 13.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy. https://app.cochat.ai/papers/10.2215/cjn.08600718
- The paper
- Thompson, A., Carroll, K., A. Inker, L., Floege, J., Perkovic, V., Boyer-Suavet, S., W. Major, R., I. Schimpf, J., Barratt, J., Cattran, D. C., S. Gillespie, B., Kausz, A., W. Mercer, A., Reich, H. N., H. Rovin, B., West, M., & Nachman, P. H. (2019). Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.08600718
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.